APA (7th ed.) Citation

S, W., M, N., L, S., M, O., R, B., H, K., . . . MED, C. (2026). Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 44(5), 400. https://doi.org/10.1200/JCO-25-01712

Chicago Style (17th ed.) Citation

S, Wang, et al. "Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 44, no. 5 (2026): 400. https://doi.org/10.1200/JCO-25-01712.

MLA (9th ed.) Citation

S, Wang, et al. "Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 44, no. 5, 2026, p. 400, https://doi.org/10.1200/JCO-25-01712.